Artificial Intelligence
2019-2030 Study on the Current Landscape of Contract Service Providers Focused on Regulatory Affairs Management for Medical Devices
Dublin, Jan. 03, 2020 (GLOBE NEWSWIRE) — The “Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030” report has been added to ResearchAndMarkets.com’s offering.
Contract Regulatory Affairs Management Market for Medical Devices, 2019-2030 report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe.
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the medical device regulatory affairs outsourcing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.
In addition, we have provided the likely distribution of the opportunity across different:
- [A] types of regulatory affair management service offered (legal representation, project registration and clinical trial application, regulatory writing and publishing and 6+ categories)
- [B] device class (class I, class II and class III)
- [C] therapeutic areas (cardiovascular disorders, central nervous system (CNS) disorders, metabolic disorders, oncological disorders, orthopedic disorders, ophthalmic disorders, pain disorders, respiratory disorders, and others)
- [D] geographical regions (North America, Europe, Asia-Pacific and rest of the world)
In 2018, the global medical devices market was estimated to have reached a net worth of approximately USD 450 billion. It is also worth noting that, since January 2018, the USFDA approved over 130 medical devices. However, a relatively large proportion of developers lack the resources and technical expertise required to handle regulatory filings and effectively manage the processes associated with procuring marketing authorizations from regional regulators.
Moreover, keeping up with evolving regulatory guidelines, rising costs of legal advice and increasing effort required for preparing of technical documentation, is difficult for companies with limited finances. In addition, establishing reimbursement strategies for medium to high-risk devices is also a complicated process and innovator companies usually do not have the expertise to deal with payers and insurance providers.
According to a recent report, 68% of medical device companies reports prepared and submitted by in-house players are either rejected or were reported to have multiple major gaps in their clinical evaluation report (CER) and supporting evidences by the notified bodies. In fact. in a survey published in the 2016 edition of Global Medical Device Supply Chain, regulatory requirements were highlighted among the primary areas of concern within the medical device value chain. Furthermore, the implementation of highly stringent regulatory guidelines, specifically for devices posing medium to high risk to consumers, render them subject to rigorous quality assessments.
The aforementioned challenges have led many medical device developers, especially the smaller players and certain established companies as well, to outsource parts of their regulatory operations to capable contract research organizations (CROs). Generally, CROs are known to offer a number of benefits, which include cost benefits, reductions in time-to-market and, in this specific case, an in-depth and up-to date regulatory support. Given that the global demand for medical devices is increasing at a substantial pace, the opportunity for CROs with expertise in regulatory affairs management is also on the rise.
In the foreseen future, the growing complexity of regulatory processes across various developing and developed geographies is likely to prompt more developers to outsource various aspects of their dealings with regulatory authorities. Moreover, in order to cope up with latest changes in medical device-related regulations, several legacy CROs are re-evaluating their operational models and business strategies. Owing to the anticipated rise in demand for such services, the contract regulatory services domain is likely to witness the entry of a number of new players in the foreseen future.
Amongst other elements, the report includes:
- A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain, and detailed analysis based on a number of relevant parameters, such as year of establishment, size of employee base, geographical location, device class (class I, class II, and class III), type and size of clientele (medical device developers, medical device manufacturers, medical device research organizations, and others), types of services offered, ([A] regulatory management services (such as legal representation, notified body selection, project registration and clinical trial application, regulatory writing and publishing, regulatory document submission, product labelling related service, gap analysis, technical dossier set-up, vigilance & medical device report, risk management-related services), [B] additional services (such as biostatistics, consulting, clinical operations, post-marketing activities, quality assurance, reimbursement, training)), region(s) of operation wherein the company is offering regulatory management services, and popular therapeutic area(s).
- A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies (such as artificial intelligence, big data analytical, blockchain, internet of things and others).
- An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia-Pacific and rest of the world (Australia, Brazil, China, India, Israel, Japan, New Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The report also features an insightful multi-dimensional, heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
- Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies (North America, Europe and Asia-Pacific). Each profile features a brief overview of the company, including information on company headquarters, year of establishment, number of employees, and therapeutic area expertise, financial information (if available), detailed description of service portfolio, and an informed future outlook.
- A benchmark analysis, highlighting the key focus areas of small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
- An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.
- An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.
To account for the uncertainties associated with the growth of the medical device regulatory affairs outsourcing CRO market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
Key Topics Covered
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Contract Research Organizations (CROs)
3.2.1. Evolution of CROs
3.3. Role of CROs in the Medical Device Industry
3.4. Types of Medical Device CROs
3.5. Types of Services Offered by CROs
3.5.1. Types of Regulatory Affairs-Related Services Offered by CROs
3.6. Need for Outsourcing Regulatory Affairs-Related Operations for Medical Devices
3.7. Key Considerations for Selecting a Suitable CRO Partner
3.8. Advantages of Working with CROs
3.9. Risks and Challenges Related to Working with CROs
3.10. Concluding Remarks
4. ROLE OF REGULATORY AFFAIRS IN MEDICAL DEVICE SUPPLY CHAIN
4.1. Chapter Overview
4.2. Overview of Medical Device Supply Chain
4.2.1. Importance of Regulatory Affairs in Medical Device Supply Chain
4.3. Factors Affecting the Medical Device Supply Chain
4.4. Key Performance Indicators for Medical Device Supply Chain Management
4.5. Optimization of Regulatory Affairs in the Medical Device Supply Chain
4.5.1. Digitalization of the Medical Device Supply Chain
5. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
5.1. Chapter Overview
5.2. General Regulatory and Reimbursement Guidelines for Medical Devices
5.3. Regulatory and Reimbursement Landscape in North America
5.3.1. The US Scenario
5.3.2. The Canadian Scenario
5.3.3. The Mexican Scenario
5.4. Regulatory and Reimbursement Landscape in Europe
5.4.1. Overall Scenario
5.4.2. The UK Scenario
5.4.3. The French Scenario
5.4.4. The German Scenario
5.4.5. The Italian Scenario
5.4.6. The Spanish Scenario
5.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
5.5.1. The Australian Scenario
5.5.2. The Brazilian Scenario
5.5.3. The Chinese Scenario
5.5.4. The Indian Scenario
5.5.5. The Israeli Scenario
5.5.6. The Japanese Scenario
5.5.7. The New Zealand Scenario
5.5.8. The Singaporean Scenario
5.5.9. The South Korea Scenario
5.5.10. The South African Scenario
5.5.11. The Taiwanese Scenario
5.5.12. The Thailand Scenario
5.6. Comparison of Regional Regulatory Environment
5.7. Concluding Remarks
6. COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. CROs Offering Regulatory Affairs-Related Services for Medical Devices: List of Companies
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Size of Employee Base
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Area of Specialization
6.2.5. Analysis by Type of Regulatory Affairs-Related Service Offered
6.2.6. Analysis by Type of Additional Services Offered
6.2.7. Analysis by Device Class
6.2.8. Analysis by Type of Clientele
6.2.9. Analysis by Medical Device Regulatory Compliance Authorities
6.2.10. Analysis by Region of Operation
6.2.11. Analysis by Popular Therapeutic Areas
6.3. Concluding Remarks
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. CROs Headquartered in North America
7.3. CROs Headquartered in Europe
7.4. CROs Headquartered in Asia-Pacific and Rest of the World
8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Benchmark Analysis: Methodology
8.3. Region-wise Benchmark Analysis
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. North America, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Europe, Peer Group VII
8.3.8. Europe, Peer Group VIII
8.3.9. Asia Pacific and Rest of the World, Peer Group IX
8.3.10. Asia Pacific and Rest of the World, Peer Group X
8.3.11. Asia Pacific and Rest of the World, Peer Group XI
8.3.12. Asia Pacific and Rest of the World, Peer Group XII
8.4. Concluding Remarks
9. GUIDE TO REGULATORY OUTSOURCING MODELS
9.1. Chapter Overview
9.2. Guiding Models for Regulatory Outsourcing
9.2.1. Functional Service Providers (FSP) Model: Large Medical Device Developers
9.2.2. End-to-End Model: Small-Sized Medical Device Developers
9.2.3. Hybrid Model: Mid-Sized Medical Device Developers
10. MEDICAL DEVICE DEVELOPER AND CRO RELATIONSHIPS: KEY VALUE DRIVERS AND PERFORMANCE INDICATORS
10.1. Chapter Overview
10.2. Definition and Importance of Key Performance Indicators
10.3. Key Considerations for Selection of Key Performance Indicators
10.4. Types of Key Performance Indicators
10.4.1. Financial Indicators
10.4.2. Process / Capability Indicators
10.4.3. Market Reputation Indicators
10.5. Comparison of Key Performance Indicators
10.6. Concluding Remarks
11. MARKET FORECAST
11.1 Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Overall Medical Device Regulatory Affairs Outsourcing Market, 2019-2030
11.4. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Geography, 2019 and 2030
11.5. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service, 2019 and 2030
11.6. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class, 2019 and 2030
11.7. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area, 2019 and 2030
11.8. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Type of Regulatory Affairs-Related Service and Geography
11.9. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Device Class and Geography
11.10. Medical Device Regulatory Affairs Outsourcing Market: Distribution by Therapeutic Area and Geography
12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways
13. SURVEY INSIGHTS
13.1. Chapter Overview
13.2. Company Specifics of Respondents
13.3. Designation of Respondents
13.4. Types of Regulatory Affairs-Related Services
13.5. Analysis by Region of Operation
13.6. Type and Size of Clientele
13.7. Average Number of Projects
13.8. Proportion of Clients Outsourcing Regulatory Affairs-Related Services
13.9. Cost of Outsourcing Regulatory Affairs-Related Services
13.10. Current and Future Market Opportunity
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. A+ Science
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Tania Persson, Business Development Manager
14.3. AtoZ-CRO
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Alexa Foltin-Mertgen, Business Development Manager
14.4. CROMSOURCE
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Troy Mccall, Chief Operating Officer
14.5. CW Research & Management
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Christian Wolflehner, Managing Director, Clinical Trial Specialist
14.6. HungaroTrial
14.6.1 Company Snapshot
14.6.2. Interview Transcript: Antal Solyom, Director of Medical Device Unit
14.7. Metrics Research
14.7.1 Company Snapshot
14.7.2. Interview Transcript: Dr. Nazish Urooj, Senior Manager, Medical & Clinical Operations
14.8. Vyomus Consulting
14.8.1 Company Snapshot
14.8.2. Interview Transcript: Dr. C Omprakash, Technical Director and Partner
15. APPENDIX I: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
- 1MED SA
- 4Clinics
- A+ Science
- Abbott
- ABIOGENESIS CLINPHARM
- ABX-CRO
- Accell Clinical Research
- Accredited Consultants
- Accutest Global
- Acorn Regulatory Consultancy Services
- Acrapack
- acromion
- aCROss Medical
- Activa Cro
- Actolis
- ADAX International
- Advanced Medical Research (AMR)
- Advena
- AE Performance Testing Lab
- Affinity Bio Partners
- Afra Pharma Consultant
- AG Mednet
- Aginko Research
- AICROS
- Al Tamimi
- Allied Clinical Management
- Allscripts Healthcare Solutions
- Alquest
- ALTIORA
- Amarex
- American Preclinical Services
- AmeRuss
- Amritt
- analyze & realize
- Andaman Medical
- Anteris Medical
- ANTRIX
- A-pharmaconsult
- apices
- APO Plus Station
- Appletree CI Group
- Arazy Group Consultants
- ARC Pharma
- Archemin
- Arlenda
- ARQon
- Asia Actual
- ATLANSTAT
- AtoZ-CRO
- Australian Healthcare Solutions
- Auxilife Scientific Services
- AVANTI
- AVIAD Life Sciences
- Axonal-Biostatem
- Azelix
- Barons Medical Consulting
- Beaufort
- Becton Dickinson
- Beijing JRJ Science and technology
- BIC Group
- BioAgile Therapeutics
- BIOCODEX Nordics
- BioFortis
- Biomapas
- Biomedical Regulatory Consulting
- Biomedical Strategy
- BioMotiv
- BioPlan
- Biorasi
- Bioreg Services
- Bioscience
- Biotech Regulatory Solutions
- BioTeknica
- BiTrial Clinical Research
- BLAU Pharmaceutical Service
- Boston Biomedical Associates (BBA)
- Boston MedTech Advisors
- Boston Scientific
- Brandwood CKC
- Bridge Pharm
- BSI
- Cactus Global
- Cardinal Health
- CardioMed Device Consultants
- Cardiovascular European Research Center (CERC)
- CARSL Consulting
- Catawba Research
- Cato Research (CATO)
- CC Clinical research Consultants
- Ceetox
- C’en Al Research
- CERES
- CHA Medical Group
- Charles River Laboratories
- ChemADVISOR
- Chemical Inspection and Regulation Service (CIRS)
- China Med Device
- Chris Freer Associates
- Clarivate Analytics
- ClinAudits
- ClinDatrix
- Clinical Device Group
- Clinical Research & Compliance Consulting
- Clinical Trial Data Services
- CliniExperts
- Clinilabs
- Clinipace
- Clinlogix
- Clinmark
- ClinMed Pharma
- ClinSync
- Clintec
- CMIC Group
- CMX Research
- Cobridge
- Commercial Eyes
- ComplianceAcuity
- Complya Consulting
- CONET
- Consultys Switzerland
- Convex
- Costello Medical
- Courante Oncology
- CPS Cortex
- Creganna Medical
- Criterium
- Cromos Pharma
- CROMSOURCE
- CROs NT
- Crown CRO
- CSSi LifeSciences
- CTI
- CTNT
- CurAccel
- CW Research & Management
- CYA Medical Device Consulting
- Dalia Givony, Regulatory & Clinical Consulting
- Databean
- Datapharm Australia
- Datavant
- Datavant
- De Groot Technical Services
- DEKRA
- devicia
- DH RegSys
- dicentra
- DiscGenics
- DKSH Marketing Services Spain
- dMed
- Donawa Lifescience Consulting
- Dor Pharmaceutical Services
- DP Clinical
- DSA Consultants
- DuPage Medical Group
- EAS Consulting Group
- EG Mont Brazil
- Eli Lily
- Emergo
- Engel, Hellyer & Partners
- EPIC Research
- Essilor
- ESTERN Medical
- Ethicare
- EuDRAcon
- Eurofins Scientific
- Eurotrials
- Evidilya
- Exalon
- ExecuPharm
- Factory CRO
- FDAInsight
- Fermish Clinical Technologies
- FGK Clinical Research
- FMD K&L
- Focal Point Research
- Fountain Medical Development (FMD)
- Fresenius Medical Care
- Freyr
- GCP-Service International
- GE Healthcare
- genae
- Genco Medical
- Genelife Clinical Research
- Genpact
- George Clinical
- Getz Healthcare
- GKM
- Global Pharma Tek
- Global Regulatory Affairs (GRA)
- Global Regulatory Partners
- Global Regulatory Services
- Green Building Japan (GBJ)
- Grove Group
- Gsap
- Gulf Medical Devices Consultancy
- Health Advances
- Health Sciences
- Healthcare International Partners
- HealthLink
- HingeClinica
- HungaroTrial
- I 3 CONSULTING
- ICBio
- ICON
- ICRC-Weyer
- ICTA
- idcOnic
- Illingworth Research Group
- INE G-MED (through G-MED North America)
- Innomar Strategies (a part of AmerisourceBergen)
- Inrextest
- Integrated Resources CRO Division
- Intel
- International HealthCare (IHC)
- Intertek Group
- Ipsum
- IQVIA
- Iris Pharma
- Ironstone Product Development
- IRW
- ISA HEALTH
- ITEC Services
- IVDeology
- IZiel Healthcare
- J Knipper
- Japan MDC (JMDC)
- Johnson & Johnson
- JSS Medical Research
- KCR
- KCRI
- KD&A
- Ken Block Consulting
- Kensington Swan
- Keystone Regulatory Services
- Kiana Systems
- Kinapse
- KLIFO
- Knoell
- Kobridge Consulting
- KPS Clinical Services
- L.S Marketing & Registration
- LabCorp
- Lambda Therapeutic Research
- Larix
- Lean RAQA
- Leon Research
- Li-Med RA & QA Experts
- Linical
- LINK Medical
- LIONBRIDGE
- LNAge
- MakroCare
- Malca Chen-Zion Group
- MANDALA International
- Mapi Group
- MasterControl
- MAXIS
- McCarthy Consultant Services
- McGee Pharma International (MPI)
- McMillan Research
- MD101 Consulting
- MD-Clinicals
- mdi Consultants
- mdi Europa
- MDP Solutions
- MED Institute
- Medelis
- Medfiles Group
- Medical Equipment Compliance Association
- Medidee
- MeDiNova Research
- MediqTrans
- Meditrial
- MEDITRIAL
- Meditrial Europe
- MedNet
- Medpace
- MedPass International
- MedQ Consultants
- Medtronic
- Medvance
- Meiji Pharmaceutical University (MPU)
- Mene Research
- Mericon
- Meshayu Consultants
- MethodSense
- Metrics Research
- MIC Medical
- Micren Healthcare
- Microsoft
- Mid-Link Consulting
- Mn Solutions
- Mobius Medical
- MolecularMD
- Morley Research Consortium
- Morula HealthTech
- Musculoskeletal Clinical Regulatory Advisers (MCRA)
- NAGLREITER
- NAMSA
- Navitas Life Sciences
- NCGS
- NEOMED Services
- Neopharm
- Neox Clinical Research
- Neozene
- Nerac
- New England Research Institutes (NERI)
- NHP Consulting
- Nordic Health Economics AB (NHE)
- Northlane Capital Partners
- Northside consulting
- Novartis
- NovaTrials
- Novem Healthcare
- Novotek
- Novum
- NSF International
- Nyprax Pharma
- O4 Research
- Obelis Group
- OmniComm Systems
- Onorach
- Operon Strategist
- OPIS
- Ora
- Osmunda
- Pace Analytical
- Pacific Bridge Medical
- Pacific Clinical Research Group (PCRG)
- Parexel
- PAREXEL Biotech
- Paxmed Interational
- Pearl Pathways
- Pepgra
- Perfect Pharmaceuticals Consultants
- Perfection-CRO
- Pharma to Market
- Pharmaceutical Regulatory Services
- Pharmaceutical Solutions
- Pharmaco-Kinesis
- Pharmahungary Group
- PharmaLex
- PharmaMed Global (through AJW Technology Consultants)
- PharmaMed Research
- PharmDedict
- PharmEng Regulatory Affairs
- PharmOut
- Phidea Group
- Pivotal
- PPD
- PQE Group
- PRA International
- Practice Fusion
- PRC Clinical
- Precision Medicine Group
- Premier Research
- Professional Regulatory Affairs
- Profil
- Promedica International
- ProMedoss
- ProPharma Group
- Prosoft Clinical
- ProTrials
- Proxima Clinical Research
- Pharmaceutical and Regulatory Services (PRSG)
- Q&R Canada
- QA Consulting
- QAdvis
- Qmed Consulting
- Qserve Group
- QST Consultations
- Q-Trials
- Qualitiso
- Qualtech Consulting
- Quanticate
- Quantum Solutions India
- Quantum Solutions India (QSI)
- QUNIQUE
- R & C Consulting Group
- R&G PharmaStudies
- R&Q
- RAMED
- RCQ Solutions
- RCRI
- ReadyClinical
- Reg-Affairs & QualiPractixis
- RegDesk
- Registrar Corp
- Regulatory Compliance Associates
- Regulatory Insight
- Regulatory Professionals
- Reimbursement Strategies
- Research Professionals
- RGL Research
- Rho
- Rook Quality Systems
- RQMIS
- RQSolutions
- RTI Health Solutions
- Safis Solutions
- Samsung Medical Center
- Saudi Telecom Company (STC)
- Scandinavian CRO
- Scandinavian Regulatory Services (SRS)
- Scope International
- SeerPharma
- Sentez CRO
- Seoul CRO
- SEQ
- SGS
- Shanghai QiSheng Business Consulting
- SHYFT Analytics
- Sidley Austin
- Siemens
- Simmons & Simmons
- Sipra Labs
- Sixmurs Group
- Society for Clinical Research Sites
- Southern Star Research
- SPARTA
- SPharm
- StarFish Medical
- STATKING Clinical Services
- SteriPack Group
- SterlingBio
- Strategic Compliance International
- StrugoPharm
- Stryker
- Sumika Chemical Analysis Service (SCAS)
- SunFlare
- Symbioteq
- Syneos Health
- Syntax
- Synteract
- TAB Clinical
- TCA Clinical Research
- TechnoSTAT
- Telecommunications Industry Association (TIA)
- The CLINICAL TRIAL Company Group
- The CRO Group
- The Integra Group
- The Society for Clinical Research Sites (SCRS)
- The Weinberg Group
- Thema Med
- Theo Manufacturing
- TheraGenesis
- TPIreg
- TRAC
- TransPerfect Life Sciences
- Trial Form Support International (TFS) (Acquired by Ratos)
- Turacoz Healthcare Solutions
- TV SD-Healthcare & Medical Devices
- UBC
- Ulmer Ventures
- Underwriters Laboratory (UL)
- Unikal Consultants
- Vantage BioTrials
- Vantage Consulting International
- Venn Life Sciences
- Veristat
- VOLER Biotech Consulting
- Volv
- Vyomus Consulting
- WCCT Global
- Wipro
- Wonderville
- WOODLEY BIOREG
- Wuxi AppTec
- Zeincro
- Zi-Medical
- Zimmer Biomet
- Zwiers Regulatory Consulting
For more information about this report visit https://www.researchandmarkets.com/r/hpcpry
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Artificial Intelligence
IG Canada Announces Enhanced Trading Platform for Enhanced User Experience
Meta description : Explore IG Canada’s advanced trading platform, educational resources, and robust security features. Achieve your trading goals with the innovative tools.
NOTTINGHAM, England, April 25, 2024 /PRNewswire/ — IG Canada, a premier online trading platform, is pleased to announce significant enhancements to its trading technology, designed to empower both novice and experienced traders with superior tools and resources. This development is part of IG Canada’s commitment to providing the best trading experience in the Canadian market.
IG Canada has upgraded its platform with advanced features that streamline trading processes and improve the accuracy of trade execution. These enhancements include customizable charts, a wider range of indicators, and improved mobile access, ensuring traders can operate efficiently from anywhere at any time.
Recognizing the importance of education in trading success, IG Canada has expanded its educational resources. The brokerage now offers a comprehensive learning center featuring webinars, tutorials, and articles that cater to various skill levels. These resources are designed to help traders develop robust trading strategies and improve their market knowledge.
Security remains a top priority for IG Canada. The latest updates include enhanced encryption and multi-factor authentication to protect client data and funds. These security measures provide peace of mind for traders, knowing their investments are safeguarded against potential threats.
IG Canada is a leading online brokerage that provides trading services across multiple asset classes, including forex, stocks, commodities, and indices. With a focus on innovation and customer service, IG Canada is committed to helping Canadian traders achieve their investment goals through a transparent and efficient trading environment.
In addition, IG Canada is committed to engaging with the community through upcoming webinars, live events, and partnerships with local financial experts. These initiatives are designed not only to support the growth and education of the clients but also to foster a stronger, more connected trading community in Canada.
Press Contact:Contact Name: Timothy C. SherwinEmail: [email protected] Phone: +447 441425053
View original content:https://www.prnewswire.co.uk/news-releases/ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience-302127189.html
Artificial Intelligence
Sentrycs Now Part of the UK National Protective Security Authority Catalog of Security Equipment
This inclusion into the NPSA CSE marks a significant milestone in the company’s commitment to enhancing national and international airspace security and to leading the C-UAS market toward multi-layer strategy optimization and excellence.
TEL-AVIV, Israel, April 25, 2024 /PRNewswire/ — Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).
Following a rigorous assessment process, Sentrycs’ cutting-edge Counter Unmanned Aerial Systems (C-UAS) solution has met the high standards set by the NPSA for Detection, Tracking, and Identification (DTI). The testing, conducted at the NPSA’s designated testing facilities in August 2023, rigorously evaluated the Sentrycs system against the NPSA’s DTI Testing and Evaluation Standard v3.1.
Sentrycs elected to be assessed under Configuration D as a 3D system with Ground Control Station (GCS) detection capability and platform identification capability, which is the most demanding test scenario with the highest number of scored parameters.
The Sentrycs system demonstrated exceptional capabilities in various security scenarios, showcasing its robustness in detecting and tracking with high accuracy and zero false alarms. The system’s innovative use of cyber techniques to extract data from targets and its streamlined human-machine interface were especially noted for their efficiency and ease of use.
“Our team is proud to have Sentrycs recognized by the UK National Protective Security Authority,” said Yoav Zaltzman, CEO of Sentrycs. “Being listed in the CSE is not just an honor; it’s a testament to our technology’s reliability and effectiveness in contributing to the ever-changing airspace security landscape.”
Sentrycs’ technology is now accessible through the NPSA CSE, providing security practitioners with verified solutions that meet the UK’s rigorous security standards. This inclusion not only underscores Sentrycs’ role in advancing security technology but also enhances its visibility and credibility on a global stage.
For more details on Sentrycs’ solutions and their impact, visit www.sentrycs.com.
For further information regarding the NPSA and the Catalog of Security Equipment, please visit the NPSA’s official website.
About Sentrycs
Sentrycs is a leader in adaptive counter-drone solutions, supported by innovative technology designed to passively identify, mitigate, and where necessary, intercept unauthorized drones custom-built for various environments – including airports, borders, prisons, critical infrastructure, and mass events. Founded in 2017, Sentrycs’ has offices in Israel and the US, serving customers worldwide. By uniting its field-proven technology and expertise in global drone environments, Sentrycs is leading the way towards a safer and more secure drone-driven future. Learn more at www.sentrycs.com
Video – https://www.youtube.com/watch?v=YBuhpTq5QuM
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment-302126952.html
Artificial Intelligence
Homestyler to Recruit First Batch of Global Partners in 20 Countries
MILAN, April 25, 2024 /PRNewswire/ — Homestyler, a leading all-in-one 3D Design platform and creative community for global designers invested by Easyhome New Retail Group and Alibaba Group, successfully hosted the Homestyler Global Partners Conference and Gorgeous Home Imported Brand Investment Promotion Conference from April 18 to 19 on the sidelines of the 2024 Salone del Mobile Milano, the world’s leading furniture fair.
Easyhome is at the forefront, driving the transformation of the home furnishing industry into a full-service platform. It has developed a tailored solution for global brands called Gorgeous Home, which includes supportive policies and has established local distribution and service networks in international markets. During the conference, Homestyler unveiled a suite of digital products enhanced by 3D and AI technologies, including cloud-based design tools, virtual livestreaming that can alter and restore furnishing scenes to true-to-life scale, a 3D Floor Planner, a 3D Virtual Studio, and a 3D Interactive Panorama, among others. The event also marked the signing ceremony with the first group of global partners.
The Global Partners Program is a key milestone of Homestyler’s roadmap towards global commercialization. It has established close partnerships with around 1,000 global home furnishing companies and design institutions to provide solutions for digital transformation. The first global partners from more than 20 countries and regions will collaborate to explore content creation and marketing potential to deliver effective growth.
In addition, Homestyler shared the unique advantages of its software and cloud designing tools, particularly in cloud rendering, free modeling capabilities, 3D model and material libraries, one-stop workflow, and user-friendliness.
“The core technologies and products of Homestyler extend through all links both online and offline and deeply converge physical experience with digital technologies, such as attracting customers, content design and creation, interactive scene, check-out tracking and more, and we continue to optimize and enhance the 3D scenario shopping experience to empower the transformation and upgrading of the global home furnishing industry,” said Ma Xingjian, head of Homestyler’s overseas business.
Looking ahead, Easyhome and Homestyler aims to establish an international service, regional distribution and dealership system, serving as a bridge between global designers and home furnishing companies worldwide to enable designers residing in different countries and regions to highlight their 3D design solutions and boost shopping experience for the consumers.
As a creative hub for global designers, Homestyler continually expands its model library with home furnishing products from around the world and provides the latest in 3D and AI technologies to help companies promote their products across various channels. Companies such as P Life Concept London, Lahoma Ltd., and Tecnobit S.r.l. are leveraging Homestyler products to enhance the online shopping experience and increase efficiency on their websites. Homestyler plans to introduce more B2B digital products and services, including advanced 3D tools for designing, modeling, rendering, virtual studio shooting, and livestreaming. “Homestyler will further advance our international development: we are planning to establish industry-academy cooperation with Italy’s top design institution, the Polytechnic University of Milan, and the relationship with ADI. With the launch of Global Partners Program, Homestyler will continue to invest in supporting policies and boost international influence through various cooperation programs, to achieve the goal of providing better design services for users globally,” said Xu Min, general manager of Homestyler.
For more information, please visit https://www.homestyler.com.
About Homestyler
Homestyler was jointly invested in by Easyhome New Retail Group and Alibaba Group. It is dedicated to provide 3D cloud design tools for designers worldwide and delivering a comprehensive suite of 3D+AI digital solutions to the furniture and home furnishing industry.
View original content:https://www.prnewswire.co.uk/news-releases/homestyler-to-recruit-first-batch-of-global-partners-in-20-countries-302127111.html
-
Uncategorized6 days ago
Generative AI gold rush drives IT spending — with payoff in question
-
Uncategorized6 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized6 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized6 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence6 days ago
Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized6 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized6 days ago
The Ottawa Hospital doctors to try AI for patient notes
-
Artificial Intelligence5 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions